Sanofi lifts 2026 sales outlook to about 10% growth at constant currencies
SNY•2026 outlook raised after strong second quarter
Sanofi raised its 2026 outlook, targeting revenue growth of about 10% at constant exchange rates.
It expects business EPS growth at constant exchange rates to run slightly above sales growth.
The upgrade follows Q2 revenue of EUR 11.6 billion, up 17.8% at constant exchange rates.
Q2 business EPS was EUR 2.09, up 33.3% at constant exchange rates.
July 2026 FX assumptions imply about a 1% revenue headwind and about a 2% headwind to business EPS.
